立他司特应该怎么购买

Xiidra is a topical ophthalmic solution whose active ingredient is lifitegrast, which is a lymphocyte function-associated antigen-1 (LFA-1) antagonist. Its purchase method and medication specifications are crucial to the treatment effect. This article will detail the purchase process, global launch status and key medication precautions of this drug.

How to purchase Litalast?

It is a prescription drug, and its purchase process needs to follow specific specifications. Understanding the formal purchase channels is very important to ensure the safety of medication.

Obtain a doctor's prescription

Patients need an ophthalmologist to diagnose dry eye syndrome and assess suitability for the use of Ritalast before issuing a prescription. The prescription should include patient information, drug specifications and usage and dosage.

Select a purchase channel

In approved countries, it can be purchased through hospital pharmacies, authorized pharmacies or certified online pharmacies. The US market price is approximately US$547 per box (0.2ml*60 bottles).

Cross-border purchase process

Chinese patients can apply for import through the "licensed drug" procedure. Complete medical records and foreign prescriptions are required. The approval cycle is usually 4-6 weeks.

When purchasing, you should be required to provide complete drug traceability information and drug purchase vouchers to ensure that you receive genuine drugs.

Domestic and overseas listing status of Ritalast

There are obvious differences in the launch progress of Ritalast globally. Understanding its approval status is of reference value for purchasing decisions.

International Approval Status

Ritalast was approved by the US FDA in July 2016, and was subsequently approved in many countries and regions such as the European Union and Canada.

Domestic Approval Status

As of now, it has not been launched in China. Data from the National Medical Products Administration shows that the drug is still in the approval stage.

Scope of Indications

It is approved for the treatment of symptoms and signs related to dry eye syndrome, and is suitable for patients who have poor response to conventional treatments such as artificial tears.

Patients can check the latest approval progress through official channels, or consult the attending physician to learn about the possibility of licensed medication.

Precautions for the use of Ritalast

The correct use of Ritalast is crucial to the therapeutic effect and medication safety. The following key matters must be strictly observed.

Correct administration method

Wash your hands before use, tilt your head back and gently pull the lower eyelid to form a pouch. After instilling 1 drop into each eye, immediately close your eyes for 1-2 minutes and avoid blinking.

Contact lens use

Contact lenses need to be removed before administration, and wait 15 minutes before re-wearing after administration to avoid direct contact between the drug and the lens.

Adverse reaction monitoring

Common adverse reactions include eye irritation, abnormal taste, etc. If you experience severe discomfort or vision changes, you should seek medical attention immediately.

Note on combined use

If other eye drops are used at the same time, the interval must be at least 5 minutes, and gel eye drops should be used last.

Patients should establish medication records, including medication time, dosage and response, and provide them to the physician for reference and evaluation during follow-up visits.